Panacea Biotec bags orders worth US$ 24 million from UN agencies
- IBEF
- December 20, 2019
Panacea Biotec has bagged orders worth Rs 170 crore (US$ 24.32 million) from UN agencies, including UNICEF, for the supply of Pentavalent vaccine.
The vaccine has a role in providing protection against five deadly diseases, including diphtheria, tetanus and hepatitis B to children.
"Panacea Biotec... has received awards worth US$ 24.32 million from U N agencies (UNICEF and PAHO) for supply of its Easy five-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib)," according to the company filing to BSE.
This award of order from UNICEF is for the calendar year 2020 and for three calendar years that include 2020 to 2022 from PAHO.
These pediatric vaccination have a major role in particular to reach the target set by United Nation under Sustainable Development Goals. The goal is to reduce under-five mortality rate to less than 25 per 1,000 live births.
"Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b - becoming the foundation of paediatric immunisation programs across the world," the company said.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
